The ARFGAP1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of human A-549 cells carrying targeted disruptions in the ARFGAP1 gene. As a polyclonal knockout product, this cell pool contains a heterogeneous mix of edited alleles, enabling robust loss-of-function studies without the need for single-cell cloning. This model provides a powerful tool for investigating ARFGAP1-dependent processes in a disease-relevant epithelial background.
A-549 cells are a widely used adherent epithelial cell line originally derived from a human lung adenocarcinoma. These cells serve as a representative model for type II alveolar epithelial cells and are extensively employed in lung cancer research, including studies of tumor cell migration, invasion, drug resistance, and secretory pathway dynamics. Their well-characterized genetic background and robust growth characteristics make them an ideal host for examining the consequences of gene knockout on lung cancer biology.
ARFGAP1 functions as a GTPase-activating protein (GAP) for the small GTPase ARF1, a master regulator of COPI-mediated vesicle formation at the Golgi apparatus. Recruited to membranes by ARF1-GTP, ARFGAP1 is regulated by upstream kinases including PKA and PAK2. It accelerates GTP hydrolysis on ARF1, generating ARF1-GDP, which triggers disassembly of the COPI coatomer complex from Golgi membranes. This activity is essential for COPI coat dynamics, retrograde trafficking from the Golgi to the endoplasmic reticulum (ER), and maintenance of Golgi architecture. ARFGAP1 directly interacts with ARF1, COPI subunits such as beta-COP and gamma-COP, and cargo receptors including the KDEL receptor and p24 proteins. By coupling GTP hydrolysis to coat disassembly, ARFGAP1 coordinates vesicle uncoating and cargo sorting, thereby controlling key steps in ER?CGolgi transport and Golgi organization.
In A-549 lung adenocarcinoma cells, loss of ARFGAP1 disrupts the normal cycle of COPI coat assembly and disassembly, leading to impaired Golgi structure, defective retrograde trafficking, and altered protein secretion. Given ARFGAP1??s role in membrane trafficking and its links to cell migration and invasion, this knockout model provides a physiologically relevant system to dissect how Golgi dysfunction contributes to cancer progression. The interplay between ARFGAP1 and ARF1 signaling is particularly significant in lung cancer, where dysregulated secretion of extracellular matrix components and growth factors can promote a metastatic phenotype.
Researchers can employ this polyclonal knockout model in a variety of experimental settings. Immunofluorescence staining for Golgi markers such as GM130 and giantin allows visualization of Golgi morphology changes. The VSVG-GFP ts045 trafficking assay can measure kinetics of ER-to-Golgi transport, while western blotting for COPI subunits and ARF1-GTP loading provides quantitative insights into ARFGAP1 functional impact. Wound healing assays are suitable for evaluating cell migration, and co-immunoprecipitation of ARFGAP1 with ARF1 or COPI components confirms interaction networks. These applications support investigations into Golgi dynamics, secretory pathway regulation, and the molecular basis of drug resistance in lung cancer. For additional information or to discuss how this model can advance your research, please contact Ascent Research.
